Search Results

Your search for Karen Lisa Smith, MD, MPH, and Vered Stearns, MD matches 2 pages

Showing 1 - 2

By Karen Lisa Smith, MD, MPH, and Vered Stearns, MD / March 15, 2014

Impact of Delayed Initiation of Adjuvant Chemotherapy for Breast Cancer Varies by Tumor Subtype

The optimal time interval between surgery and initiation of adjuvant chemotherapy for early-stage breast cancer is not well established. Although most physicians aim to initiate adjuvant chemotherapy within a few weeks of surgery, clinical factors may cause delay. The influence of delay on relapse...

breast cancer

By Karen Lisa Smith, MD, MPH, and Vered Stearns, MD / June 25, 2014

A New Era in the Management of Advanced HER2-Positive Breast Cancer

Approximately 20% of all breast cancers are human epidermal growth factor receptor 2 (HER2)-positive. Prior to the era of HER2-targeted therapy, HER2-positive breast cancer was characterized by a poor prognosis.1,2 The development of the first HER2-targeted therapy, trastuzumab (Herceptin), led to...

Apr

Today In Oncology

Search Results

Your search for Karen Lisa Smith, MD, MPH, and Vered Stearns, MD matches 2 pages

Impact of Delayed Initiation of Adjuvant Chemotherapy for Breast Cancer Varies by Tumor Subtype

A New Era in the Management of Advanced HER2-Positive Breast Cancer

Adagrasib Plus Cetuximab in KRAS G12C–Mutated Colorectal Cancer

Induction and Concurrent Vismodegib With Radiation Therapy for Locally Advanced Unresectable Basal Cell Carcinoma

FDA Approves Nogapendekin Alfa Inbakicept-pmln for BCG-Unresponsive Non–Muscle Invasive Bladder Cancer

Predicting Ovarian Cancer Relapse With Spatial Tissue Analysis

Chemohormonal Therapy for Locally Advanced Prostate Cancer